Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia

NCT04175587 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04175587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04175587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia
Lead sponsor
Peking University People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
December 1, 2019
Completion date
August 31, 2023
Enrollment
109 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukaemia